PMA

P110041: ADVIA CENTAUR HBSAGII

FDA PMA · Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen) · Siemens Corp.

Key facts

PMA number P110041
Trade name ADVIA CENTAUR HBSAGII
Generic name Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen)
Applicant Siemens Corp.
Owner/operator SIEMENS HEALTHCARE DIAGNOSTICS INC.
Product code LOM
Approval date May 16, 2014
Docket number 14M-0692
Notice date Jun 10, 2014
Establishment registration 2432235
FEI number 2432235

At a glance

  • 10–99 Supplements
  • Oct 17, 2025 Latest supplement decision
  • No Withdrawn
  • Yes Summary of safety and effectiveness on file
  • 1–9 UDI device identifiers (GUDID)
  • None MAUDE adverse event reports
  • None Recall events

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About PMA approvals

Premarket approval (PMA) is the FDA's most stringent review pathway, required for most Class III devices that support or sustain life or present a potentially unreasonable risk.

Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date:

Browse all PMA approvals